MRK · News · 20260821N
Keytruda Patent Expiration Outlook
Merck & Co., Inc. · 2026-08-21 · Importance 56 · Surprise 24
Third-party analysts identified Keytruda’s expected loss of exclusivity in 2028 as a major strategic and valuation risk for Merck. The articles characterized Merck as heavily reliant on Keytruda and questioned whether its oncology pipeline and diversification can offset the eventual patent-related revenue pressure. This concern contributed to mixed analyst views despite positive clinical news and recent stronger-than-expected results.